Regenerative Medicine
Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026
Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine
Pelage Pharmaceuticals Raises $120M to Advance Hair Loss Regenerative Therapy to Phase 3 Trials
Pelage Pharmaceuticals; hair loss; regenerative medicine; PP405; Phase 3 clinical trial; Series B financing; stem cell therapy; androgenetic alopecia
Pfizer Veteran Suneet Varma Named CEO of Phase 3-Ready Biotech Startup Intent Biologics
Suneet Varma; Pfizer vet; Intent Biologics; CEO appointment; regenerative medicine; Phase 3 clinical trials; biotech startup; inflammation and immunology
Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey
cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine
FDA Approves Humacyte’s Symvess ATEV: A Breakthrough in Regenerative Medicine for Vascular Trauma Treatment
Humacyte, FDA approval, Symvess ATEV, regenerative medicine, vascular trauma, lab-grown blood vessels
Aurion Biotech’s AURN001 Shows Significant Vision Improvement in Phase 1/2 Trial for Corneal Edema
AURN001, corneal edema, corneal endothelial dysfunction, allogeneic cell therapy, regenerative medicine, clinical trial results
uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130
uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)
Astellas Expands Cell Therapy Research with New Japan Site for Universal Cells
Astellas, Universal Cells, cell therapy, regenerative medicine, Japan research site, allogeneic cell therapy
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation